• Explore /
  • Poster
  • / Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Abstract Poster

Authors

null

Zhen Zeng

Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China, Guangzhou, China

Zhen Zeng , Wei Wei , Lanyue Cui , Zhihao Jiang , Jundong Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT04157491

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5598)

DOI

10.1200/JCO.2023.41.16_suppl.5598

Abstract #

5598

Poster Bd #

293

Abstract Disclosures

Similar Posters

First Author: Wei Wei

First Author: Qin Xu

First Author: Mario Javier Pineda

First Author: Christian Marth